secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001193125-22-202719
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials
--------------------------------------------------------------------------------

- Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.
- Funds to complete enrollment and data readouts in three ongoing Phase 3 trials of posoleucel.
- New investors include Kite (Gilead), F2 Ventures, ElevateBio, Invus, Redmile, EcoR1 Capital, GMT Capital.
- Offering expected to close July 28, 2022; no underwriter. Cash & equivalents $172.7M as of June 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/0001193125-22-202719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/d286495d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-202719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer